Last edition
News about "Pegfilgrastim Biosimilar"
Lupin Secures US FDA Approval for Pegfilgrastim Biosimilar Armlupeg
Lupin has received approval from the U.S. Food and Drug Administration (FDA) for its biosimilar Armlupeg (pegfilgrastim-unne), marking an important milestone in the company’s biologics journey. Armlupeg is a biosimilar to Neulasta (pegfilgrastim), a widely used therapy that helps reduce infection risk in cancer patients undergoing chemotherapy.
Pegfilgrastim Biosimilar | 01/12/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy